| A215 |
Lebrikizumab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Lebrikizumab is an IgG4 humanized monoclonal antibody that specifically binds to interleukin-13 (IL-13) and inhibits its function. Lebrikizumab can be used for the research of asthma. |
.png)
|
| A217 |
IMA-026 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A218 |
GSK 679586 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A219 |
Abrezekimab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Abrezekimab (VR 942) contains CDP7766, a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. Abrezekimab can be used in research of asthma. |
.png)
|
| A220 |
Cendakimab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC50s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis). |
.png)
|
| A221 |
Dectrekumab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research. |
.png)
|
| A222 |
CNTO 607 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A223 |
Tralokinumab Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD). |
.png)
|
| A224 |
H2L6 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A225 |
M1295 Biosimilar（Anti-IL-13 Reference Antibody）
Featured
|
|
|
| A226 |
Eblasakimab Biosimilar（Anti-IL-13Ra1 / CD213a1 Reference Antibody）
Featured
|
|
|
| A227 |
Wake Forest U. patent anti-IL-13RA2 Biosimilar（Anti-IL-13Ra2 / CD213a2 Reference Antibody）
Featured
|
|
|
| A228 |
Ordesekimab Biosimilar（Anti-IL-15 Reference Antibody）
Featured
|
Ordesekimab (AMG 714; PRV-015) is a fully human IgG1κ anti-IL-15 (Interleukin Related) monoclonal antibody. The binding of Ordesekimab to IL-15 inhibits the interaction of IL-15 with the IL-2Rβ and common γ chain of the IL-15 receptor complex, but not with the IL-15Rα chain. Ordesekimab has the potential for study of nonresponsive celiac disease (NRCD). |
.png)
|
| A229 |
DISC0280 Biosimilar（Anti-IL-15 Reference Antibody）
Featured
|
|
|
| A230 |
Brodalumab Biosimilar（Anti-IL-17Ra / CD217 Reference Antibody）
Featured
|
Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis. |
|
| A231 |
GSK 1070806 Biosimilar（Anti-IL-18 Reference Antibody）
Featured
|
|
|
| A232 |
ABT-325 Biosimilar（Anti-IL-18 Reference Antibody）
Featured
|
|
|
| A233 |
Gevokizumab Biosimilar（Anti-IL-1b Reference Antibody）
Featured
|
Gevokizumab is a potent anti-IL-1β antibody, negatively modulates IL-1β signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1β for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II). |
.png)
|
| A234 |
CDP484 Biosimilar（Anti-IL-1b Reference Antibody）
Featured
|
|
|
| A235 |
Canakinumab Biosimilar（Anti-IL-1b Reference Antibody）
Featured
|
Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin. |
.png)
|
| A236 |
AMG 108 Biosimilar（Anti-IL-1R1 / CD121a Reference Antibody）
Featured
|
|
|
| A237 |
Nidanilimab Biosimilar（Anti-IL-1RAP / IL-1R3 Reference Antibody）
Featured
|
Nidanilimab (CAN04) is a fully humanized monoclonal anti-IL1RAP antibody with a Kd value of 1.10 pM. Nidanilimab blocks IL1α and IL1β signaling and stimulates the immune system to destroy tumour cells. Nidanilimab can be used in research of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) . |
.png)
|
| A238 |
Melrilimab Biosimilar（Anti-IL-1RL1 / ST2 / IL-33R Reference Antibody）
Featured
|
Melrilimab (GSK 3772847) is an IgG2-kappa anti-IL1RL1/ST2/IL33R/DER4/FIT-1 monoclonal antibody. Melrilimab can be used for the research of asthma. |
.png)
|
| A239 |
Astegolimab Biosimilar（Anti-IL-1RL1 / ST2 / IL-33R Reference Antibody）
Featured
|
Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. Astegolimab has the potential for chronic obstructive pulmonary disease (COPD) research. |
.png)
|
| A240 |
Imsidolimab Biosimilar（Anti-IL-1RL2 / IL-36R Reference Antibody）
Featured
|
Imsidolimab (ANB 019) is a high-affinity, humanized monoclonal antibody of anti-IL-36R. Imsidolimab antagonizes IL-36 cytokine signal transduction. Imsidolimab has potential application in generalized pustular psoriasis (GPP) and other inflammatory skin diseases. |
.png)
|
| A241 |
Fletikumab Biosimilar（Anti-IL-20 Reference Antibody）
Featured
|
Fletikumab (NNC0109-0012) is a monoclonal antibody targeting to IL-20. Fletikumab can be used for inflammation research, such as rheumatoid arthritis. |
.png)
|
| A242 |
Cheng Kung U. patent anti-IL-20 Biosimilar（Anti-IL-20 Reference Antibody）
Featured
|
|
|
| A243 |
Cheng Kung U. patent anti-IL-20R1 Biosimilar（Anti-IL-20Ra Reference Antibody）
Featured
|
|
|
| A244 |
Avizakimab Biosimilar（Anti-IL-21 Reference Antibody）
Featured
|
Avizakimab (BOS161721) is a humanized IgG1 monoclonal antibody that targets interleukin-21. |
.png)
|
| A245 |
Lilly patent anti-IL-21 Biosimilar（Anti-IL-21 Reference Antibody）
Featured
|
|
|
